Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
Belgium
Study Type
Interventional
Intervention
exenatide (Byetta)
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring T2DM, exenatide, HbA1c, weight, waist circumference, insulin sensitivity, beta-cell function
Eligibility Criteria
Inclusion Criteria:
- type 2 diabetes subjects
- 40 to 80 years
- body mass index (BMI) between 25 and 40 kg/m²
- baseline glycated haemoglobin (HbA1c) > 7.0 %, despite a maximally-tolerated combined oral therapy with a BCF stimulant (sulfonylurea or repaglinide) plus metformin
Exclusion Criteria:
- previous or current use of glitazone
- previous use of systemic glucocorticoids, weight-reducing drug(s) such as sibutramine
- previous exposure to GLP-1 receptor agonist or DPP-4 inhibitors
Sites / Locations
- Cliniques universitaires St-Luc
Outcomes
Primary Outcome Measures
Improvement in HbA1c
Secondary Outcome Measures
Non-invasive modeling of glucose homeostasis determinants, including insulin sensitivity
Full Information
NCT ID
NCT00948168
First Posted
July 27, 2009
Last Updated
July 30, 2009
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
1. Study Identification
Unique Protocol Identification Number
NCT00948168
Brief Title
Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes
Official Title
6-Months Exenatide and Glucose Homeostasis Determinants in Type 2 Diabetic Patients
Study Type
Interventional
2. Study Status
Record Verification Date
July 2009
Overall Recruitment Status
Completed
Study Start Date
July 2008 (undefined)
Primary Completion Date
July 2009 (Actual)
Study Completion Date
July 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine in type 2 diabetic patients in secondary failure to combined oral therapy whether, besides improvement in glycemic control, addition of exenatide, a new drug introduced to treat diabetes before addition of insulin to current therapy, over 6 months is associated with improvement in beta-cell function, insulin sensitivity following 24-hours discontinuation of the drug.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
T2DM, exenatide, HbA1c, weight, waist circumference, insulin sensitivity, beta-cell function
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
34 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
exenatide (Byetta)
Intervention Description
all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
Primary Outcome Measure Information:
Title
Improvement in HbA1c
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Non-invasive modeling of glucose homeostasis determinants, including insulin sensitivity
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
type 2 diabetes subjects
40 to 80 years
body mass index (BMI) between 25 and 40 kg/m²
baseline glycated haemoglobin (HbA1c) > 7.0 %, despite a maximally-tolerated combined oral therapy with a BCF stimulant (sulfonylurea or repaglinide) plus metformin
Exclusion Criteria:
previous or current use of glitazone
previous use of systemic glucocorticoids, weight-reducing drug(s) such as sibutramine
previous exposure to GLP-1 receptor agonist or DPP-4 inhibitors
Facility Information:
Facility Name
Cliniques universitaires St-Luc
City
Brussels
State/Province
Brabant
ZIP/Postal Code
1200
Country
Belgium
12. IPD Sharing Statement
Learn more about this trial
Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes
We'll reach out to this number within 24 hrs